Detalhe da pesquisa
1.
Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Rheumatol Int
; 37(9): 1469-1479, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28597306
2.
The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis.
J Korean Med Sci
; 31(2): 202-7, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26839473
3.
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.
Ann Rheum Dis
; 72(5): 741-4, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23161899
4.
Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries.
Med Sci Monit
; 17(4): SR1-13, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21455121
5.
The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome.
Int J Rheumatol
; 2019: 9698086, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31191660
6.
Cardiovascular effects of methotrexate in rheumatoid arthritis revisited.
Curr Med Chem
; 22(16): 1903-10, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25876749
7.
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Arthritis Res Ther
; 17: 95, 2015 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25889308
8.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Arthritis Rheum
; 58(10): 2968-80, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18821691
9.
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
J Rheumatol
; 31(9): 1804-10, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15338504